Goldman Sachs: Raises target price for Sino Biopharmaceutical (01177.HK) to HK$9.07, reiterates "Buy" rating.

Zhito Finance APP has learned that Goldman Sachs issued a research report stating that Sino Biopharmaceutical (01177.HK) announced plans to acquire an additional 5% equity interest in its subsidiary Chia Tai Tianqing for RMB 4.48 billion in cash, at a valuation of approximately 19 times trailing twelve months P/E; upon completion, its effective shareholding will rise from 60% to 65%. Goldman Sachs kept its 2026 earnings forecast for the company broadly unchanged, raised its 2027 and 2028 earnings forecasts by 9.1% each, maintained a "Buy" rating, and raised its target price from HKD 8.65 to HKD 9.07.